Answers are grounded in this paper and cite their sources.
Case report reveals parkinsonism worsened by cabozantinib in melanoma treatment, suggesting drug-disease interaction.
BACKGROUND Immune checkpoint inhibitors (ICIs) are a cornerstone in the treatment of advanced melanoma. Although neurologic immune-related adverse events (irAEs) are increasingly recognized, parkinsonism remains exceedingly rare. Fewer than five cases of ICI-associated parkinsonism have been published.1,2 Melanoma itself is linked to an increased risk of Parkinson’s disease (PD), potentially due to overlapping biological pathways involving α-synuclein.3,4 Cabozantinib, a tyrosine kinase inhibitor (TKI), has not been previously associated with Parkinsonian symptoms. We present a case of immunotherapy-induced parkinsonism, with symptom exacerbation following initiation of tyrosine kinase inhibitor therapy. Case presentation: A 68-year-old male with metastatic melanoma and Hurthle cell carcinoma developed resting tremor, bradykinesia, rigidity, and micrographia shortly after completing pembrolizumab therapy. Examination revealed left-sided cogwheel rigidity and tremor, with reduced arm swing, but preserved gait without shuffling, consistent with parkinsonism. In 2024, he began cabozantinib for metastatic Hurthle cell carcinoma. Shortly after starting, he experienced worsening of motor symptoms. He was started on carbidopa-levodopa 25/100 mg TID. At follow-up, he reported overall improvement but continued to experience cyclical exacerbations during weeks 2 and 3 of his treatment cycle. His regimen was adjusted: 25/100 mg TID during weeks 1 and 4, and 50/100 mg TID during weeks 2 and 3. At his next visit, he showed resolution of resting tremor and only mild left upper extremity rigidity. DISCUSSION This case raises the question of whether pembrolizumab directly induced parkinsonism or unmasked subclinical PD in a melanoma patient. The exacerbation pattern during cabozantinib therapy is novel and may indicate drug-disease interaction or altered dopaminergic responsiveness. Symptom resolution with a tailored Sinemet regimen supports dopaminergic pathway involvement. CONCLUSION This case underscores the importance of recognizing parkinsonism as a rare irAE of ICIs. The reproducible symptom fluctuations during TKI therapy warrant further investigation into the potential neuropharmacological effects of cabozantinib.
No takes yet. Share an insight, caveat, or question.
Singer et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: